[Herpes zoster and postherpetic neuralgia: advantages of the vaccination].
Cañada
José Luis Merino
JL
Centro de Salud de Algorta, Bilbao, Spain.
D000368:Aged; D000998:Antiviral Agents; D002648:Child; D000075202:Contraindications; D004342:Drug Hypersensitivity; D005260:Female; D006562:Herpes Zoster / Q000276:immunology / Q000517:prevention & control*; D053061:Herpes Zoster Vaccine / Q000009:adverse effects / Q000627:therapeutic use*; D014645:Herpesvirus 3, Human / Q000276:immunology; D006801:Humans; D007115:Immunization Schedule; D008875:Middle Aged; D051474:Neuralgia, Postherpetic / Q000188:drug therapy / Q000276:immunology / Q000517:prevention & control* / Q000523:psychology; D010146:Pain / Q000188:drug therapy / Q000209:etiology; D011247:Pregnancy; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D013030:Spain / Q000453:epidemiology; D017211:Treatment Failure
D000998:Antiviral Agents; D053061:Herpes Zoster Vaccine